Prognostic factors and therapeutic effects of different treatment modalities for colorectal cancer liver metastases

Table 4 Comparison of clinicopathology between not-near great vessel group (A) and near great vessel group (B)

	A	B	Statistics	P value
Gender			χ2 = 0.048	0.826
Male	48	13
Female	21	5
Age (yr)	59.22 ± 10.34	63.11 ± 12.90	t = 1.350	0.181
Primary tumor size (cm)	4.73 ± 1.84	5.75 ± 2.65	t = 1.900	0.061
Primary tumor site			χ2 = 0.519	0.771
Right colon	18	4
Left colon	23	5
Rectum	28	9
Pathological type			χ2 = 0.456	0.500
Non-MUC	60	15
MUC	19	3
Differentiation			χ2 = 4.581	0.101
High	16	3
Medium	42	8
Low	11	7
CEA (ng/mL)			χ2 = 0.315	0.574
≤ 15	45	13
> 15	24	5
CA19-9 (U/mL)			χ2 = 0.654	0.419
≤ 37	49	11
> 37	20	7
LMN			χ2 = 0.001	0.971
No	31	8
Yes	38	10
CLM distribution			χ2 = 2.546	0.280
Right lobe	32	5
Left lobe	9	2
Both lobes	28	11
CLM number			χ2 = 3.206	0.073
≤ 4	43	7
> 4	26	11
Maximum CLM diameter (cm)	4.04 ± 1.97	4.19 ± 1.69	t = 0.309	0.758
Postoperative chemotherapy time			χ2 = 1.766	0.184
≤ 6 mo	59	13
> 6 mo	10	5
CLM treatments			χ2 = 23.693	0.000
Drug	12	1
Ablation	21	2
Intervention	5	10
Surgical resection	31	5

MUC: Mucinous colorectal adenocarcinomas; CEA: Carcinoembryonic antigen; CA19-9: Cancer antigen 19-9; LMN: Lymph node metastases; CLM: Colorectal liver metastases.